SCHOFIELD, Wis., April 12, 2013 /PRNewswire/ -- Healthcare product developer PuraMed BioScience®, Inc. (PMBS: OTCBB) announced plans this week to expand the retail sales efforts of its OTC migraine product LipiGesic® M to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target, food store chains such as SuperValu, Kroger and Safeway, and additional well-known regional drugstores. PuraMed has selected its targeted retailers according to various material criteria, including cost of entry, geography, demographics and consumer preference.
LipiGesic M currently has national distribution in some of the largest chain drug stores in the United States, including Walgreen's and CVS Pharmacy stores, with the number of retail outlets now stocking LipiGesic M migraine product approaching 15,000 stores.
To support its retail effort, the Company also plans on embarking on a national marketing campaign to promote, and increase distribution, for its non-prescription migraine relief product LipiGesic M. Recent published scientific evidence has confirmed LipiGesic M as a highly effective, over-the-counter medication for the treatment of acute migraine pain.
In addition to LipiGesic M, PuraMed BioScience also has plans to launch LipiGesic H, a remedy for tension-type headaches, as well as LipiGesic PM, a remedy for insomnia and other sleep disorders. The planned marketing campaign, along with financing now in place, will allow the Company to develop the launch programs for these additional products and build out PuraMed's product portfolio in 2013.
Product Financing in Place
In July 2012, the Company signed an agreement with TCA Global for a $2,000,000 equity line of credit, which now allows PuraMed the ability to fulfill product orders and shipments, increase marketing and promotional budgets, across all key media venues, and will be instrumental in getting the Company's products in more retail store shelves.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches as well as LipiGesic PM, which provides a remedy for insomnia and other sleep disorders.
For more information on PuraMed BioScience, visit www.PuraMedBioScience.com, join the company's group page on Facebook by searching "PuraMed BioScience" and/or follow the company on Twitter at www.twitter.com/puramed.
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
CONTACT: Melissa Diaz
South Street Media, Inc
Phone: (917) 937-8968
SOURCE PuraMed BioScience, Inc.